The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints,...


Syndax Pharmaceuticals Inc released updated results from its Phase 2 study dubbed ENCORE 601 that evaluated its Entinostat in combination with Merck's Keytruda for treating non-small cell lung cancer, or NSCLC, previously treated with both chemotherapy and PD- 1 therapy. At the time of data cut-off, there were seven confirmed partial responses among the overall population of 72 efficacy-evaluable patients, for a 10 percent objective response rate, a median duration of response of 5.3 months, and a median progression free survival of 2.8 months, the company said.



from Biotech News